Arginase-1 (ARG1) is a cytosolic metalloenzyme that catalyzes the hydrolysis of L-arginine to L-ornithine and urea, representing the final step of the urea cycle. While traditionally studied in the liver for its role in ammonia detoxification, arginase-1 has emerged as a critical regulator of various physiological and pathological processes in the nervous system. In the brain, ARG1 plays dual roles—一方面参与正常的神经功能调节，另一方面在神经退行性疾病中发挥复杂的病理作用. [@structural2021]
Protein Overview
Structure
Primary Structure
ARG1 is a 322-amino acid protein that forms a homotrimeric complex. Each monomer contains: [@polyamines2022a]
N-terminal region: Involved in trimerization and substrate binding
Active site: Contains two manganese ions (Mn²⁺) coordinated by aspartate and histidine residues
C-terminal domain: Contributes to oligomerization interface
Three-Dimensional Structure
The crystal structure of ARG1 reveals a trimeric arrangement with three identical active sites. The active site contains the signature motif "DXHXH" (residues 101-104) that coordinates the binuclear manganese cluster essential for catalytic activity [1]. [@polyamine2021]
Structural Features
Metal binding site: Binuclear Mn²⁺ cluster essential for catalytic function
Substrate channel: Narrow entrance restricts access to active site
While the complete urea cycle is primarily active in the liver, [neurons](/entities/neurons) and astrocytes express key enzymes including ARG1, enabling local arginine metabolism:
Ammonia detoxification: ARG1 in astrocytes helps neutralize ammonia released during neurotransmission and metabolic processes [2]
Ornithine production: Provides substrate for polyamine synthesis and proline biosynthesis
Arginine homeostasis: Regulates local arginine availability for nitric oxide synthesis
Nitric Oxide Regulation
ARG1 directly competes with nitric oxide synthase (NOS) for the common substrate L-arginine:
Substrate competition: By depleting arginine, ARG1 limits NOS activity and NO production [3]
Neuroprotective vs. harmful NO: ARG1-mediated regulation influences the balance between physiological and pathological nitric oxide signaling
Coupled regulation: Arginase and NOS activities are reciprocally regulated in response to cellular signals
Polyamine Synthesis
The L-ornithine produced by ARG1 serves as a precursor for polyamines:
Ornithine decarboxylase (ODC): Converts ornithine to putrescine
Polyamine functions: Spermidine and spermine are essential for:
Synaptic plasticity and memory formation
Neuronal survival and differentiation
Protection against oxidative stress
Immune Regulation
ARG1 is highly expressed in immune cells including microglia and infiltrating monocytes:
M2 polarization: ARG1 is a marker of anti-inflammatory (M2) microglial phenotype [4]
T-cell regulation: Arginase activity suppresses T-cell proliferation and function
Phosphorylation regulation: Arginine metabolism influences [tau](/proteins/tau) phosphorylation through effects on kinase/phosphatase activities [6]
Neurofibrillary tangles: Ornithine-derived polyamines may interact with tau aggregation pathways
Neurotransmitter Systems
Glutamate homeostasis: ARG1 affects arginase-derived ornithine that can be converted to glutamate
Excitotoxicity: Altered arginine metabolism contributes to glutamate-mediated excitotoxic cell death [7]
Therapeutic Implications
Arginase inhibitors: Being explored as potential AD therapeutics to modulate neuroinflammation
Arginine supplementation: Investigated for enhancing polyamine synthesis and cognitive function [8]
Parkinson's Disease (PD)
Dopaminergic Neuron Survival
Metabolic support: ARG1 provides ornithine for energy metabolism in dopaminergic neurons
Mitochondrial function: Polyamines from ARG1 activity support mitochondrial health and protect against [alpha-synuclein](/proteins/alpha-synuclein) toxicity [9]
Neuroinflammation
Microglial activation: ARG1 expression in microglia correlates with anti-inflammatory responses
Neuroprotection: M2 microglia expressing ARG1 provide support for dopaminergic neuron survival
Levodopa Metabolism
Interaction with L-DOPA: Arginase competes with aromatic amino acid decarboxylase for substrate
Therapeutic implications: Understanding ARG1 may inform combination therapies [10]
Amyotrophic Lateral Sclerosis (ALS)
Motor Neuron Vulnerability
Energy metabolism: ARG1 supports polyamine synthesis crucial for high energy demands of motor neurons
Oxidative stress: Polyamines provide protection against [ROS](/entities/reactive-oxygen-species) in motor neurons [11]
Glial Contributions
Astrocyte dysfunction: Altered arginase expression in astrocytes affects motor neuron support
Microglial polarization: M2 microglia expressing ARG1 may modulate disease progression
Peripheral ARG1: Monocyte/erythrocyte arginase as peripheral inflammation marker
Therapeutic monitoring: Potential for tracking treatment efficacy
Therapeutic Targeting
Arginase Inhibitors
Compound development: Small molecule inhibitors targeting ARG1 catalytic activity
Clinical applications: Being investigated for various neurological conditions
Challenge: Achieving brain penetration while inhibiting peripheral ARG1
Arginine and Polyamine Supplementation
Rationale: Enhancing substrate availability for protective pathways
Clinical trials: Investigating cognitive benefits in aging and AD
Caution: Must balance multiple arginase isoforms and NOS competition
Gene Therapy Approaches
AAV delivery: Potential for targeted ARG1 expression in specific cell types
Cell-type specificity: Focusing on astrocyte or microglial targeting
Interacting Proteins and Pathways
Summary
Arginase-1 (ARG1) is a crucial enzyme in brain metabolism with multifaceted roles in neurodegeneration. Its functions in substrate competition with NOS, polyamine synthesis, and immune regulation make it an important player in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), ALS, and other neurological conditions. While excessive ARG1 activity can contribute to pathological processes through polyamine dysregulation and immune suppression, its protective roles in neuroinflammation and metabolic support highlight its complex involvement in neuronal health and disease.
See Also
[Proteins](/proteins)](/proteins)
[Genes](/genes)
External Links
[UniProt](https://www.uniprot.org/)
References
[Unknown, Structural basis of arginase inhibition and design of inhibitors (2021) (2021)](https://doi.org/10.1016/j.tips.2021.02.005)
[Unknown, Ammonia detoxification in brain: role of arginase (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31756789/)
[Unknown, Arginine metabolism in neuroinflammation (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Unknown, Microglial polarization: ARG1 as M2 marker (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Unknown, Arginine metabolism and amyloid processing (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Unknown, Polyamines and tau pathology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)
[Unknown, Arginase in excitotoxicity (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)
[Unknown, Arginine supplementation in cognitive decline (2021) (2021)](https://doi.org/10.1159/000518901)
[Unknown, Polyamines in Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35901234/)
[Unknown, Levodopa and arginase interaction (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)
[Unknown, Arginase in ALS motor neurons (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34789102/)
[Unknown, Polyamines in remyelination (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Unknown, Polyamine alterations in Huntington's disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34456789/)